Aplagon raises €4.8M to expand antithrombotic into new Phase II trial
What's the deal? Finnish biotech Aplagon has raised €4.8M to expand Phase II development of APAC, a first-in-class antiplatelet and anticoagulant therapy for thrombo-inflammatory diseases. The funding will support a new Phase II clinical programme targeting arteriovenous fistula (AVF) maturation failure in patients with end-stage kidney disease.
The round was led by existing investors Fåhraeus Startup and GrowthDealroom has a profile for this one. Try Dealroom → AB and the European Innovation Council Fund, with continued backing from the Jenny and Antti Wihuri FoundationDealroom has a profile for this one. Try Dealroom →, InnovestorDealroom has a profile for this one. Try Dealroom →, and the Gösta Serlachius Fine Arts FoundationDealroom has a profile for this one. Try Dealroom →. Aplagon has now raised more than €20M through equity and non-dilutive funding to date.
APAC mimics naturally occurring molecules that regulate coagulation and inflammation in damaged blood vessels. More than 70 participants have received the drug so far, with no significant safety concerns observed.
Why now? Aplagon recently filed a clinical trial application with the European Medicines Agency for the AVF programme, and in March 2026 it dosed the first patient in its Phase IIa HEALING trial for chronic limb-threatening ischemia (CLTI) in Finland. The company is building momentum across two indications simultaneously.
AVF maturation failure is a major unmet need in haemodialysis. AVFs — surgically created connections between an artery and a vein for dialysis access — often fail to mature for long-term use. Aplagon estimates around 130,000 new AVFs are created annually in the US alone, with roughly half failing to mature adequately. That leads to repeat procedures, hospitalisation, and higher costs.
What could go wrong? Aplagon is a small biotech running two Phase II programmes on modest funding. Clinical setbacks in either CLTI or AVF could stall progress. The drug's localised mechanism is novel but unproven at scale, and the path from Phase II to market in vascular medicine is long and expensive.
Competition from established antithrombotic therapies also poses a risk, as does the challenge of demonstrating clear superiority or differentiation in hospital-based settings.
The signal: Aplagon remains an early-stage company by Dealroom's classification, yet it has assembled over €20M in total funding from a mix of public institutions and private backers — a capital-efficient profile that aligns with growing investor interest in platform biotechs that can pursue multiple clinical indications from a single mechanism. The repeat participation of both Fåhraeus Startup and Growth and the European Innovation Council Fund suggests conviction in APAC's dual-indication strategy at a stage where many clinical biotechs struggle to secure follow-on financing.
Read more: european-biotechnology.com
